The forecast for both adjusted sales growth and adjusted operating profit for the full year is expected to end at 0 to a decline of 6 percent at constant exchange rates, compared with a previously expected decline of 4-12 percent.
Adjusted sales in the second quarter of this year rose 7 percent to 78.5 billion Danish kroner compared with the same period last year, beating analysts' expectations of 71.6 billion Danish kroner.
Adjusted operating profit increased 11 percent year-on-year to DKK 33.4 billion, compared with an expected DKK 28.9 billion.
The company launched a new tablet form of Wegovy in the US in January - where it has been a huge success - and the tablet was recently approved for use in Europe.
